HR-Positive Breast Cancer: Adjuvant Oral SERDs and Implications for Clinical Practice

This segment explores the evolving role of oral selective estrogen receptor degraders in early-stage hormone receptor–positive, HER2-negative breast cancer and their potential impact on treatment paradigms. Dr. Adam Brufsky introduces emerging data from adjuvant studies, highlighting the possibility of a new endocrine therapy option and raising questions about how these agents may compare with established approaches such as CDK4/6 inhibitor–based therapy.

Dr. Hope S. Rugo discusses the complexity of integrating oral SERDs into clinical practice, particularly in the absence of mature survival data, and emphasizes the need to consider sequencing strategies and patient selection. Dr. Mabel Mardones highlights the importance of risk stratification, noting that treatment decisions may differ between higher- and lower-risk patients.

The discussion then shifts to real-world implementation, with Dr. Lisa Raff and Ms. Lori Brisbin emphasizing that adoption will depend on regulatory approval, guideline inclusion, and payer coverage. Overall, this segment highlights both the clinical promise and practical considerations shaping the future use of oral SERDs.